Pharming Group reports first quarter 2026 financial

The FDA approved Pharming's Joenja for treating children aged 4-11 with APDS, a rare immunodeficiency. The Dutch biopharma firm (PHARM) expects the new pediatric doses to be available in the US in October. This marks the first FDA-approved treatment for this age group with APDS.

Pharming Group (PHAR) said Joenja (leniolisib) has started commercial sales in Japan for APDS patients aged 4 and older, after inclusion on Japan’s NHI price list. The drug is an oral PI3K delta inhibitor approved based on a Phase III trial and supported by long-term extension data. OrphanPacific is the local partner.

Pharming Group N.V. (PHAR) furnished an SEC Form 6-K — earnings release. Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., dated July 30, 2026. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja mom

Pharming Group cut its 2026 revenue guidance by $30 million to $375 million to $395 million, citing weaker Q2 sales and continued weakness in its legacy Ruconest product. Q2 revenue was $90.2 million versus $100.8 million consensus. Ruconest sales fell 10% to $72.3 million, below $83.8 million. Operating profit was $1.3 million.

Pharming Group N.V. reported Q2 2026 total revenues of US$90.2m, down 3% year over year. RUCONEST revenue was US$72.3m, down 10% YoY, while Joenja (leniolisib) revenue rose to US$17.9m, up 40% YoY. Q2 operating profit fell to US$1.3m. The company revised 2026 revenue guidance to US$375m-395m and operating expense guidance to US$315m-320m.

European stocks rose slightly after Israel and Lebanon agreed to renew a fragile ceasefire, while oil prices fell more than 1% toward $96/bbl. STOXX 600 added 0.2% to 622.14; DAX +0.6% and CAC 40 +0.8%, but FTSE 100 -0.4% as BP and Shell dragged. Vivendi -4.6%; Remy Cointreau +11%; UMG -5.6%; CMC Markets +13%.